| Amy Zeglen, PCC-S | |
|
380 S Portage Path, Akron, OH 44320-2326 | |
| (330) 315-4918 | |
| Not Available |
| Full Name | Amy Zeglen |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 380 S Portage Path, Akron, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003276668 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | E. 0808098 (Ohio) | Primary |
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | E. 0808098 (Ohio) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Amy Zeglen, PCC-S 725 E Market St, Akron, OH 44305-2421 Ph: (330) 434-4141 | Amy Zeglen, PCC-S 380 S Portage Path, Akron, OH 44320-2326 Ph: (330) 315-4918 |
News Archive
Matthew Feddersen and Blake Marggraff from Lafayette, Calif. were awarded the top prize at the Intel International Science and Engineering Fair, a program of Society for Science & the Public. They received $75,000 and the Gordon E. Moore Award, in honor of the Intel co-founder and retired chairman and CEO, for developing a potentially more effective and less expensive cancer treatment that places tin metal near a tumor before radiation therapy.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million. OrbiMed Advisors, LLC, led the financing with participation from existing Relypsa investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners.
Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.
Research led by a Dignity Health St. Joseph's Hospital and Medical Center physician on ovarian cancer was published in the Feb. 24, 2016 issue of New England Journal of Medicine. The research was directed by Bradley J. Monk, M.D. and researchers at 12 other medical facilities around the nation.
› Verified 3 days ago
Dr. James M Athans, PCC/S, LICDC, SAP Counselor Medicare: Not Enrolled in Medicare Practice Location: 212 East Exchange St, Greenleaf Family Center, Akron, OH 44304 Phone: 330-376-9494 Fax: 330-376-4525 | |
Shelli Fullum, Counselor Medicare: Not Enrolled in Medicare Practice Location: 611 W Market St, Akron, OH 44303 Phone: 330-996-4600 Fax: 330-643-0767 | |
Brianne Markley, Counselor Medicare: Not Enrolled in Medicare Practice Location: 340 S Broadway St, Akron, OH 44308 Phone: 330-253-3100 | |
Marshon Whitley, LCDCIII Counselor Medicare: Not Enrolled in Medicare Practice Location: 665 W Market St, Akron, OH 44303 Phone: 330-379-3467 Fax: 330-379-3465 | |
Patricia Dudley, MSED, LPCC-S, LICDC Counselor Medicare: Not Enrolled in Medicare Practice Location: 18 N Forge St, Akron, OH 44304 Phone: 330-762-0591 | |
Maribeth Lieberth, M.A. L.P.C. Counselor Medicare: Not Enrolled in Medicare Practice Location: 900 Mull Ave, Akron, OH 44313 Phone: 800-621-5207 |